SomnoMed Limited (ASX:SOM)

Market Cap	173.46M
Revenue (ttm)	111.49M
Net Income (ttm)	-3.46M
Shares Out	218.18M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	83.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55,603
Average Volume	37,026
Open	0.7800
Previous Close	0.7900
Day's Range	0.7750 - 0.7950
52-Week Range	0.2400 - 0.8500
Beta	0.99
RSI	61.38
Earnings Date	Aug 22, 2025

About SomnoMed

SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper te...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1987
• Employees: 300
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SOM

Financial Performance

In 2025, SomnoMed's revenue was 111.49 million, an increase of 21.65% compared to the previous year's 91.65 million. Losses were -3.46 million, -71.77% less than in 2024.